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Summary
Clinical characteristics
SLC39A14 deficiency is characterized by evidence between ages six months and three years of delay or loss of 
motor developmental milestones (e.g., delayed walking, gait disturbance). Early in the disease course, children 
show axial hypotonia followed by dystonia, spasticity, dysarthria, bulbar dysfunction, and signs of parkinsonism 
including bradykinesia, hypomimia, and tremor. By the end of the first decade they develop severe, generalized, 
pharmaco-resistant dystonia, limb contractures, and scoliosis, and lose independent ambulation. Cognitive 
impairment appears to be less prominent than motor disability. Some affected children have succumbed in their 
first decade due to secondary complications such as respiratory infections.
Diagnosis/testing
The diagnosis of SLC39A14 deficiency is established in a proband with progressive dystonia-parkinsonism (often 
combined with other signs such as spasticity and parkinsonian features), characteristic neuroimaging findings, 
hypermanganesemia, and biallelic pathogenic variants in SLC39A14 on molecular genetic testing.
Management
Treatment of manifestations: Symptomatic treatment includes physiotherapy and orthopedic management to 
prevent contractures and maintain ambulation; use of adaptive aids (walker or wheelchair) for gait 
abnormalities; and use of assistive communication devices. Support by a speech and language/feeding specialist 
and nutritionist to assure adequate nutrition and to reduce the risk of aspiration. When an adequate oral diet can 
no longer be maintained, gastrostomy tube placement should be considered. Antispasticity medications 
(baclofen and botulinum toxin) and L-dopa have had limited success. While chelation therapy with intravenous 
administration of disodium calcium edetate early in the disease course shows promise, additional studies are 
warranted.
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Prevention of primary manifestations: Unknown, but disodium calcium edetate chelation therapy shows promise; 
additional studies are warranted.
Surveillance: Routine monitoring of:
• Height and weight using age- and gender-appropriate growth charts;
• Swallowing and diet to assure adequate nutrition;
• Ambulation and speech;
• Whole-blood manganese levels and brain MRI to assess treatment response and disease progression.
Agents/circumstances to avoid:
• Environmental manganese exposure (i.e., contaminated drinking water, occupational manganese 
exposure in welding/mining industries, contaminated ephedrone preparations)
• High manganese content of total parenteral nutrition
• Foods very high in manganese, including: cloves; saffron; nuts; mussels; dark chocolate; pumpkin, sesame, 
and sunflower seeds
Evaluation of relatives at risk: Molecular genetic testing for the familial SLC39A14 pathogenic variants of 
apparently asymptomatic younger sibs of an affected individual allows early identification of sibs who would 
benefit from prompt initiation of treatment and preventive measures.
Genetic counseling
SLC39A14 deficiency is inherited in an autosomal recessive manner. Heterozygotes (carriers) are asymptomatic 
and are not at risk of developing the disorder. At conception, each sib of an affected individual has a 25% chance 
of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not 
a carrier. Once the SLC39A14 pathogenic variants have been identified in an affected family member, carrier 
testing of at-risk relatives, prenatal testing for a pregnancy at increased risk, and preimplantation genetic 
diagnosis are possible.
Diagnosis
Suggestive Findings
SLC39A14 deficiency should be suspected in individuals with typical clinical, neuroimaging, and laboratory 
findings [Tuschl et al 2016]:
• Clinical findings. Infantile or early-childhood onset of:
⚬ Delay in acquisition of developmental motor milestones or loss of developmental motor milestones;
⚬ Progressive pharmaco-resistant dystonia;
⚬ Parkinsonism signs (tremor, bradykinesia, hypomimia);
⚬ Bulbar dysfunction;
⚬ Dysarthria.
• Neuroimaging. Brain MRI findings characteristic of manganese deposition (Figure 1) including T1-
weighted hyperintensity of the following:
⚬ Globus pallidus and striatum, with thalamic sparing;
Note: Basal ganglia changes on T1-weighted imaging are accompanied by T2-weighted 
hypointensity.
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⚬ White matter including the cerebellum, spinal cord, and dorsal pons, with sparing of the ventral 
pons;
⚬ Anterior pituitary gland.
• Laboratory findings. Hypermanganesemia. Whole-blood manganese levels are markedly elevated, usually 
above 1,000 nmol/L (normal reference range <320 nmol/L).
Establishing the Diagnosis
The diagnosis of SLC39A14 deficiency is established in a proband with progressive dystonia (often combined 
with other signs such as spasticity and parkinsonian features), characteristic neuroimaging findings, 
hypermanganesemia, and identification of biallelic pathogenic variants in SLC39A14 on molecular genetic 
testing [Tuschl et al 2016] (see Table 1).
Molecular genetic testing approaches can include a combination of gene-targeted testing (single-gene testing or 
a multigene panel) and genomic testing (comprehensive genomic sequencing) depending on the phenotype.
Gene-targeted testing requires the clinician to determine which gene(s) are likely involved, whereas genomic 
testing does not. Because the phenotype of SLC39A14 deficiency is likely to be broad, children with the 
suggestive clinical, laboratory, and neuroimaging findings could be diagnosed using gene-targeted testing (see 
Option 1), whereas those with early-onset dystonia-parkinsonism indistinguishable from other inherited 
disorders with parkinsonism-dystonia are more likely to be diagnosed using genomic testing (see Option 2).
Option 1
When the clinical, laboratory, and brain MRI findings suggest the diagnosis of SLC39A14 deficiency, molecular 
genetic testing approaches can include single-gene testing and use of a multigene panel.
• Single-gene testing. Sequence analysis of SLC39A14 is performed first. If only one pathogenic variant is 
found, gene-targeted deletion/duplication analysis could be considered; however, to date no exon or 
whole-gene deletions have been reported.
Figure 1. A. Axial T1-weighted image showing the hyperintensity of the globus pallidus (white arrows), and the cerebral white matter 
(dashed arrows)
B. Axial T2-weighted image showing the hypointensity of the globus pallidus (white arrows)
C. Sagittal T1-weighted image showing the hyperintensity of the white matter in the cerebellum, spinal cord and dorsal pons with 
sparing of the ventral pons (white arrow), and the anterior pituitary (dashed arrow)
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• A multigene panel that includes SLC39A14 and other genes of interest (see Differential Diagnosis) may 
also be considered.
Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene 
vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not 
associated with the condition discussed in this GeneReview; thus, clinicians need to determine which 
multigene panel provides the best opportunity to identify the genetic cause of condition at the most 
reasonable cost while limiting identification of pathogenic variants in genes that do not explain the 
underlying phenotype. (3) Methods used in a panel may include sequence analysis, deletion/duplication 
analysis, and/or other non-sequencing-based tests.
For an introduction to multigene panels click here. More detailed information for clinicians ordering 
genetic tests can be found here.
Option 2
When the phenotype is indistinguishable from other movement disorders, molecular genetic testing approaches 
can include a combination of genomic testing (comprehensive genomic sequencing; recommended) or gene-
targeted testing (multigene panel; to consider).
• Recommended testing. Comprehensive genomic testing (when available) includes exome sequencing and 
genome sequencing. For an introduction to comprehensive genomic testing click here. More detailed 
information for clinicians ordering genomic testing can be found here.
• Testing to consider. A multigene panel that includes SLC39A14 and other genes of interest (see 
Differential Diagnosis) may be considered; however, given the rarity of SLC39A14 deficiency, many panels 
for inherited dystonia-parkinsonism and/or this complex neurologic phenotype may not include this gene. 
For an introduction to multigene panels click here. More detailed information for clinicians ordering 
genetic tests can be found here.
Table 1. Molecular Genetic Testing Used in SLC39A14 Deficiency
Gene 1 Test Method Proportion of Probands with Pathogenic Variants 2 Detectable by This Method
SLC39A14
Sequence analysis 3 7/7 6
Gene-targeted deletion/duplication 
analysis 4 None reported
1. See Table A. Genes and Databases for chromosome locus and protein.
2. See Molecular Genetics for information on allelic variants detected in this gene.
3. Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. 
Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon 
or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click here.
4. Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include: quantitative 
PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect 
single-exon deletions or duplications.
5. No data on detection rate of gene-targeted deletion/duplication analysis are available.
6. Five reported consanguineous families [Tuschl et al 2016] and two other families, one consanguineous and one non-consanguineous 
[Author, personal observation]
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Clinical Characteristics
Clinical Description
SLC39A14 deficiency has only recently been identified in 11 individuals from seven families [Tuschl et al 2016; 
Author, personal observation]; therefore, information on the phenotypic spectrum and disease progression is 
limited.
Onset occurs between ages six months and three years. Affected children present with delay or loss of motor 
developmental milestones (e.g., delayed walking, gait disturbance).
Early in the disease course, children show axial hypotonia followed by dystonia, spasticity, dysarthria, bulbar 
dysfunction, and signs of parkinsonism including bradykinesia, hypomimia, and tremor.
By the end of the first decade, they develop severe, generalized, pharmaco-resistant dystonia, limb contractures, 
scoliosis, and loss of independent ambulation.
Although there appears to be relative cognitive sparing (psychometric testing has not been possible), a degree of 
learning disability is present in all children.
Some affected children succumb in their first decade due to secondary complications such as respiratory 
infections.
Neuropathology. The neuropathologic findings in one individual with SLC39A14 deficiency [Tuschl et al 2016] 
included:
• Extensive gliosis and neuronal loss in the globus pallidus and dentate nucleus;
• Preservation of neurons in the cerebral and cerebellar cortex as well as the caudate, putamen, and 
thalamus;
• A vacuolated myelinopathy with patchy axonal loss in the cerebral and cerebellar white matter.
Genotype-Phenotype Correlations
No genotype-phenotype correlations are known.
Prevalence
The disease prevalence is not established. To date only 11 individuals with SLC39A14 deficiency from seven 
families have been identified. These seven families are from different ethnic backgrounds and six are 
consanguineous [Tuschl et al 2016; Author, personal observation].
Genetically Related (Allelic) Disorders
No phenotypes other than those discussed in this GeneReview are known to be associated with pathogenic 
variants in SLC39A14.
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Differential Diagnosis
Table 2. Disorders to Consider in the Differential Diagnosis of SLC39A14 Deficiency
Disorder Gene(s) MOI
Clinical Features of This Disorder
Overlapping with SLC39A14 
Deficiency
Distinguishing from SLC39A14 
Deficiency
Disorders of 
manganese 
homeostasis
Dystonia/parkinsonism, 
hypermanganesemia, 
polycythemia, and 
chronic liver disease 
(SLC30A10 deficiency)
SLC30A10 AR
• Dystonia-parkinsonism
• Hypermanganesemia
• Brain MRI features 
consistent w/
manganese deposition
• Presents with 
polycythemia, abnormal 
iron indices, & liver 
disease in addition to the 
neurologic phenotype
• Absence of Mn deposition 
in the liver w/T1 
hyperintensity on liver 
MRI
Acquired 
hypermanganesemia 1 N/A N/A
• Often presents w/
psychiatric symptoms
• History of Mn exposure 
from environmental 
sources, parenteral 
nutrition, or contaminated 
ephedrone preparations
Acquired hepatocerebral 
degeneration 2 N/A N/A
• Liver disease is the 
predominant feature; it 
precedes development of 
neurologic symptoms.
Early-onset 
NBIA 
disorders (see 
NBIA 
Overview)
PKAN PANK2 AR
• Parkinsonism-dystonia
• T2-weighted 
hypointensity of the 
globus pallidus on brain 
MRI
• Usually presents w/
additional clinical features 
(e.g., pigmentary 
retinopathy, optic atrophy, 
oculomotor abnormalities, 
axonal neuropathy, 
cognitive decline, seizures)
• Lacks the T1-weighted 
hyperintensity of the 
globus pallidus on brain 
MRI due to Mn deposition
PLAN PLA2G6 AR
MPAN C19orf12 AR
BPAN WDR45 XL
FAHN FA2H AR
Kufor-Rakeb syndrome ATP13A2 AR
CoPAN COASY AR
Disorders of 
copper 
metabolism
Wilson disease ATP7B AR • Parkinsonism-dystonia
• Liver disease, psychiatric 
symptoms, low serum 
ceruloplasmin & high 
non-ceruloplasmin-bound 
serum copper
• No Mn deposition on 
brain MRI
Inherited 
forms of 
dystonia (see 
Dystonia 
Overview)
DYT1 early-onset 
isolated dystonia TOR1A AD
• Early-onset generalized 
dystonia
• No features consistent 
w/Mn deposition on brain 
MRI
• Absent 
hypermanganesemia
KMT2B-related early-
onset dystonia KMT2B AD
MECR-related 
childhood-onset 
dystonia and optic 
atrophy 3
MECR AR
• Additional optic atrophy
• No features consistent 
w/Mn deposition on brain 
MRI
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Table 2. continued from previous page.
Disorder Gene(s) MOI
Clinical Features of This Disorder
Overlapping with SLC39A14 
Deficiency
Distinguishing from SLC39A14 
Deficiency
SLC6A3-related 
dopamine transporter 
deficiency syndrome
SLC6A3 AR
• Parkinsonism-dystonia
• No features consistent 
w/Mn deposition on brain 
MRI
Tyrosine hydroxylase-
deficient dopa-
responsive dystonia
TH AR
GTP cyclohydrolase 1-
deficient dopa-
responsive dystonia
GCH1 AD
Sepiapterin reductase 
deficiency dopa-
responsive dystonia
SPR AR
Inherited Forms of Parkinson Disease (see Parkinson Disease 
Overview)
Inherited neurodegenerative/metabolic disorders
(see Dystonia Overview, Table 4 for hereditary 
neurodegenerative or metabolic
disorders characterized by complex dystonia)
• Complex dystonia
• No features consistent 
w/Mn deposition on brain 
MRI
AD = autosomal dominant; AR = autosomal recessive; BPAN = beta-propeller protein-associated neurodegeneration; CoPAN = 
COASY protein-associated neurodegeneration; FAHN = fatty acid hydroxylase-associated neurodegeneration. Mn = manganese; MOI 
= mode of inheritance; MPAN = mitochondrial membrane protein-associated neurodegeneration; NBIA = neurodegeneration with 
brain iron accumulation; PKAN = pantothenate kinase-associated neurodegeneration; PLAN = PLA2G6-associated 
neurodegeneration; XL = X-linked
1. Mortimer et al [2012], Santos et al [2014], Janocha-Litwin et al [2015]
2. Miletić et al [2014]
3. Heimer et al [2016]
Management
Evaluations Following Initial Diagnosis
To establish the extent of disease and needs in an individual diagnosed with SLC39A14 deficiency, the following 
evaluations are recommended:
• Neurologic examination for dystonia, parkinsonism, and spasticity, including evaluation of ambulation 
and speech
• Assessment for physiotherapy, occupational therapy, and/or speech therapy
• Evaluation of swallowing and nutritional status
• Brain MRI, if not performed as part of the diagnostic evaluation
• Assessment of whole-blood manganese levels, if not performed as part of the diagnostic evaluation
• Consultation with a clinical geneticist and/or genetic counselor
Treatment of Manifestations
Symptomatic treatment. Early initiation of physiotherapy and orthopedic management aims to prevent 
contractures and maintain ambulation. As needed, individuals should be referred for adaptive aids (e.g., a walker 
or wheelchair for gait abnormalities) and assistive communication devices.
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Support by a speech and language/feeding specialist and nutritionist is indicated to assure adequate nutrition 
and to reduce the risk of aspiration. When an adequate oral diet can no longer be maintained, gastrostomy tube 
placement should be considered. Gastric feeding tube and/or tracheostomy may be required to prevent 
aspiration pneumonia.
Note that symptomatic treatment with L-dopa and antispasticity medications including benzodiazepines, 
baclofen, and botulinum toxin has been attempted with limited success. There has been partial but poorly 
sustained response to trihexyphenidyl at high doses of 20 mg/day and intrathecal baclofen of 1,500-2,000 µg/day 
in two older sibs reported by Tuschl et al [2016].
Chelation therapy. Disodium calcium edetate, which primarily promotes the urinary excretion of manganese, 
was given intravenously (20 mg/kg/dose) twice daily for five days each month to a female age five years with 
SLC39A14 deficiency [Tuschl et al 2016]. After six months of treatment, neurologic manifestations improved 
and the child regained the ability to walk.
In contrast, treatment of a female age 17 years with advanced disease (severe generalized dystonia with 
prominent oromandibular involvement, contractures, and scoliosis) did not affect disease progression as she 
continued to deteriorate with worsening tremor and stiffness. Hence, it is likely necessary to initiate chelation 
treatment early in the disease course.
It is anticipated that chelation therapy will need to be lifelong.
Potential adverse effects of disodium calcium edetate chelation therapy include thrombocytopenia and 
leukopenia, nephrotoxicity, hepatoxicity, hypocalcemia, and trace metal and vitamin deficiencies [Lamas et al 
2012]. Monitoring includes the following:
• Complete blood count
• Assessment of renal function including urinalysis assessed at baseline and monthly thereafter. Monitoring 
may be extended to every other month once on a stable dose.
• Assessment of liver function
• Measurement of the concentrations of electrolytes, calcium, magnesium, and phosphate
• Measurement of the concentrations of trace metals (manganese, zinc, copper, and selenium)
• Assessment of iron status
Treatment may need to be discontinued if:
• White blood count is <3.5x109/L
• Neutrophil count is <2.0x109/L
• Platelet count is <150x109/L
• >2+ proteinuria is detected on more than one occasion (with no evidence of infection)
The above cut-off values are based on guidelines for D-penicillamine treatment [Chakravarty et al 2008]. 
Because chelation treatment with disodium calcium edetate may prevent early death and reduce morbidity in 
SLC39A14 deficiency, lower cut-off values may be acceptable. For each affected individual, the benefits of clinical 
treatment need to be carefully weighed against the risk of adverse effects.
Prevention of Primary Manifestations
Chelation therapy with disodium calcium edetate may prevent primary disease manifestations in affected sibs 
who are asymptomatic (see Treatment of Manifestations).
Surveillance
Routine monitoring of:
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• Height and weight using age and gender appropriate growth charts;
• Swallowing and diet to assure adequate nutrition;
• Ambulation and speech;
• Whole-blood manganese levels and brain MRI to assess treatment response and disease progression.
Agents/Circumstances to Avoid
The following should be avoided:
• Environmental manganese exposure (i.e., contaminated drinking water, occupational manganese 
exposure in welding/mining industries, contaminated ephedrone preparations)
• High manganese content of total parenteral nutrition
• Foods very high in manganese, including: cloves; saffron; nuts; mussels; dark chocolate; and pumpkin, 
sesame, and sunflower seeds
Evaluation of Relatives at Risk
Molecular genetic testing of apparently asymptomatic younger sibs of an affected individual for the familial 
SLC39A14 pathogenic variants allows early identification of sibs who would benefit from prompt initiation of 
treatment and preventive measures (see Agents/Circumstances to Avoid).
See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.
Therapies Under Investigation
Search ClinicalTrials.gov in the US and www.ClinicalTrialsRegister.eu in Europe for access to information on 
clinical studies for a wide range of diseases and conditions.
Genetic Counseling
Genetic counseling is the process of providing individuals and families with information on the nature, inheritance, 
and implications of genetic disorders to help them make informed medical and personal decisions. The following 
section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for 
family members. This section is not meant to address all personal, cultural, or ethical issues that individuals may 
face or to substitute for consultation with a genetics professional. —ED.
Mode of Inheritance
SLC39A14 deficiency is inherited in an autosomal recessive manner. Six of the seven families reported to date 
were consanguineous.
Parents of a proband
• The parents of an affected child are obligate heterozygotes (i.e., carriers of one SLC39A14 pathogenic 
variant).
• Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.
Sibs of a proband
• At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being 
an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.
• Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.
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Offspring of a proband. The offspring of an individual with SLC39A14 deficiency are obligate heterozygotes 
(carriers) for a pathogenic variant in SLC39A14.
Other family members. Each sib of the proband's parents is at a 50% risk of being a carrier of a SLC39A14 
pathogenic variant.
Carrier (Heterozygote) Detection
Carrier testing for at-risk relatives requires prior identification of the SLC39A14 pathogenic variants in the 
family. Carrier testing for reproductive partners of known carriers is appropriate, particularly if consanguinity is 
likely.
Related Genetic Counseling Issues
See Management, Evaluation of Relatives at Risk for information on evaluating at-risk relatives for the purpose 
of early diagnosis and treatment.
Family planning
• The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the 
availability of prenatal testing is before pregnancy.
• It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and 
reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.
DNA banking is the storage of DNA (typically extracted from white blood cells) for possible future use. Because 
it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in 
the future, consideration should be given to banking DNA of affected individuals.
Prenatal Testing and Preimplantation Genetic Diagnosis
Once the SLC39A14 pathogenic variants have been identified in an affected family member, prenatal testing for a 
pregnancy at increased risk and preimplantation genetic diagnosis are possible.
Differences in perspective may exist among medical professionals and within families regarding the use of 
prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather 
than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of 
the parents, discussion of these issues is appropriate.
Resources
GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries 
for the benefit of individuals with this disorder and their families. GeneReviews is not responsible for the 
information provided by other organizations. For information on selection criteria, click here.
No specific resources for SLC39A14 Deficiency have been identified by GeneReviews staff.
Molecular Genetics
Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables 
may contain more recent information. —ED.
Table A. SLC39A14 Deficiency: Genes and Databases
Gene Chromosome Locus Protein HGMD ClinVar
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Table A. continued from previous page.
SLC39A14 8p21.3 Zinc transporter ZIP14 SLC39A14 SLC39A14
Data are compiled from the following standard references: gene from HGNC; chromosome locus from OMIM; protein from UniProt. 
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click here.
Table B. OMIM Entries for SLC39A14 Deficiency (View All in OMIM)
608736 SOLUTE CARRIER FAMILY 39 (ZINC TRANSPORTER), MEMBER 14; SLC39A14
617013 HYPERMANGANESEMIA WITH DYSTONIA 2; HMNDYT2
Molecular Genetic Pathogenesis
SLC39A14 encodes a divalent metal transporter that is required for cellular uptake of manganese [Tuschl et al 
2016]. It plays a crucial role as a regulator of manganese homeostasis by facilitating manganese uptake into the 
liver for subsequent excretion in bile.
Biallelic SLC39A14 pathogenic variants are thought to impair hepatic manganese uptake and lead to 
accumulation of manganese in the blood. Subsequent deposition of manganese in the brain, particularly the 
globus pallidus, results in manganese toxicity and causes progressive dystonia (often combined with other signs 
such as spasticity and parkinsonian features) [Tuschl et al 2016].
Gene structure. SLC39A14 comprises nine exons and encodes four transcripts. Two transcripts differ by an 
alternative 5'UTR (NM_001128431.2 and NM_001135153). Alternative splicing of exon 4 and 9 generates two 
alternative transcripts (NM_015359.4 and NM_001135154.1).
Pathogenic variants. Homozygous or compound heterozygous SLC39A14 pathogenic variants documented in 
seven families include missense, nonsense and deletion variants (see Table 3).
Pathogenic variants are predicted to (1) cause a significantly truncated protein because of a frameshift and 
premature stop codon, (2) affect an evolutionary highly conserved area of the protein, or (3) lead to abnormal 
splicing. Therefore, these sequence changes have detrimental effects on protein function [Tuschl et al 2016].
Table 3. SLC39A14 Variants Discussed in This GeneReview
DNA Nucleotide Change Predicted Protein Change Reference Sequences
c.292T>G p.Phe98Val
NM_015359.4
NP_056174.2
c.313G>T p.Glu105Ter
c.367C>T p.Gln123Ter
c.477_478delCA p.Ser160CysfsTer5
c.512G>A p.Gly171Glu
c.1147G>A p.Gly383Arg
c.1407C>G p.Asn469Lys
c.751-9C>G 1, 2 p.His251ProfsTer26 1
Note on variant classification: Variants listed in the table have been provided by the authors. GeneReviews staff have not independently 
verified the classification of variants.
Note on nomenclature: GeneReviews follows the standard naming conventions of the Human Genome Variation Society 
(varnomen.hgvs.org). See Quick Reference for an explanation of nomenclature.
1. cDNA analysis confirmed an eight-nucleotide insertion (c.751_752insCTTCCAGC) from intron 5 indicating that this variant creates 
a new splice-acceptor site [Author, personal observation].
2. g.22,273,273C>G (GRCh37/hg19)
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Normal gene product. SLC39A14 encodes three protein isoforms. Isoforms 1 (NP_001121903) and 2 
(NP_056174) have 492 amino acids; isoform 3 (NP_001128626) has 481 amino acids. They contain eight 
transmembrane domains, a histidine-rich motif (HXHXHX), and a metalloprotease motif (H/EEXPHEXGD) 
required for metal transport [Taylor et al 2005, Tominaga et al 2005].
Only isoforms 1 and 2 have been studied in detail; both localize to the plasma membrane and transport 
manganese, iron, zinc, and cadmium. While isoform 1 is ubiquitously expressed, expression of isoform 2 is 
restricted to liver, gastrointestinal tract, kidney, and pancreas with no expression in the brain. Isoform 2 is 
thought to act as the main regulator of manganese homeostasis, facilitating hepatic manganese uptake for biliary 
excretion [Tuschl et al 2016].
Abnormal gene product. SLC39A14 pathogenic variants described in affected individuals (Table 3) have 
deleterious effects on protein function. While wild-type SLC39A14 expressed in HEK-293 cells facilitates 
manganese uptake, mutated SLC39A14 results in greatly reduced manganese uptake [Tuschl et al 2016].
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